Search

Your search keyword '"Fehrmann, Rudolf S.N."' showing total 115 results
Start Over Author "Fehrmann, Rudolf S.N."
115 results on '"Fehrmann, Rudolf S.N."'

3. Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Author

Visconti, Alessia, Rossi, Niccolò, Deriš, Helena, Lee, Karla A, Hanić, Maja, Trbojević-Akmačić, Irena, Thomas, Andrew M., Bolte, Laura A., Björk, Johannes R., Hooiveld-Noeken, Jahlisa S., Board, Ruth, Harland, Mark, Newton-Bishop, Julia, Harries, Mark, Sacco, Joseph J., Lorigan, Paul, Shaw, Heather M., de Vries, Elisabeth G.E., Fehrmann, Rudolf S.N., Weersma, Rinse K., Spector, Tim D., Nathan, Paul, Hospers, Geke A. P., Sasieni, Peter, Bataille, Veronique, Lauc, Gordan, and Falchi, Mario

Published
2023
Full Text
View/download PDF

4. FIRRM/C1orf112 is synthetic lethal with PICH and mediates RAD51 dynamics

Author

Stok, Colin, Tsaridou, Stavroula, van den Tempel, Nathalie, Everts, Marieke, Wierenga, Elles, Bakker, Femke J., Kok, Yannick, Alves, Inês Teles, Jae, Lucas T., Raas, Maximilian W.D., Huis in 't Veld, Pim J., de Boer, H. Rudolf, Bhattacharya, Arkajyoti, Karanika, Eleftheria, Warner, Harry, Chen, Mengting, van de Kooij, Bert, Dessapt, Julien, ter Morsche, Lars, Perepelkina, Polina, Fradet-Turcotte, Amelie, Guryev, Victor, Tromer, Eelco C., Chan, Kok-Lung, Fehrmann, Rudolf S.N., and van Vugt, Marcel A.T.M.

Published
2023
Full Text
View/download PDF

6. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma

Author

Rossi, Niccolò, Lee, Karla A., Bermudez, Maria V., Visconti, Alessia, Thomas, Andrew Maltez, Bolte, Laura A., Björk, Johannes R., de Ruijter, Laura Kist, Newton-Bishop, Julia, Harland, Mark, Shaw, Heather M., Harries, Mark, Sacco, Joseph, Board, Ruth, Lorigan, Paul, de Vries, Elisabeth G.E., Segata, Nicola, Taams, Leonie S., Papa, Sophie, Spector, Tim D., Nathan, Paul, Weersma, Rinse K., Hospers, Geke A.P., Fehrmann, Rudolf S.N., Bataille, Veronique, and Falchi, Mario

Published
2022
Full Text
View/download PDF

9. Neo-Adjuvant Immune Checkpoint Inhibition In Endometrial Cancer Expands Transcriptional Footprints Associated With Tertiary Lymphoid Structures: Implications For Future Immunotherapy

Author

Brummel, Koen, Requesens, Marta, Bhattacharya, Arkajyoti, Somefun, Feija, Van Rooij, Nienke, Plat, Annechien, Van Der Hall, Dimas M.X., Vledder, Annegé, Wardenaar, René, Spierings, Diana C.J., Berezikov, Eugene, Bosse, Tjalling, Foijer, Floris, Bart, Joost, Nijman, Hans W., Fehrmann, Rudolf S.N., and De Bruyn, Marco

Published
2025
Full Text
View/download PDF

10. MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

Author

CTC, MS CGO, Pathologie, Cancer, Metman, Madelon J.H., Jonker, Pascal K.C., Sondorp, Luc H.J., van Hemel, Bettien M., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Robinson, Dominic J., van Dam, Gooitzen M., Links, Thera P., Coppes, Rob P., Fehrmann, Rudolf S.N., Kruijff, Schelto, CTC, MS CGO, Pathologie, Cancer, Metman, Madelon J.H., Jonker, Pascal K.C., Sondorp, Luc H.J., van Hemel, Bettien M., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Robinson, Dominic J., van Dam, Gooitzen M., Links, Thera P., Coppes, Rob P., Fehrmann, Rudolf S.N., and Kruijff, Schelto

Published
2024

11. MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer

Author

Metman, Madelon J.H., Jonker, Pascal K.C., Sondorp, Luc H.J., van Hemel, Bettien M., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Robinson, Dominic J., van Dam, Gooitzen M., Links, Thera P., Coppes, Rob P., Fehrmann, Rudolf S.N., Kruijff, Schelto, Metman, Madelon J.H., Jonker, Pascal K.C., Sondorp, Luc H.J., van Hemel, Bettien M., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Robinson, Dominic J., van Dam, Gooitzen M., Links, Thera P., Coppes, Rob P., Fehrmann, Rudolf S.N., and Kruijff, Schelto

Abstract

Purpose: Multifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection. Methods: A phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy. Results: Fourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound. Conclusion: EMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.

Published
2024

18. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Author

van Not, Olivier J., Wind, Thijs T., Ismail, Rawa K., Bhattacharya, Arkajyoti, Jalving, Mathilde, Blank, Christian U., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B., Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, van Rijn, Rozemarijn S., Stevense-den Boer, Marion, van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Blokx, Willeke A.M., Suijkerbuijk, Karijn P.M., Fehrmann, Rudolf S.N., Hospers, Geke A.P., van Not, Olivier J., Wind, Thijs T., Ismail, Rawa K., Bhattacharya, Arkajyoti, Jalving, Mathilde, Blank, Christian U., Aarts, Maureen J.B., van den Berkmortel, Franchette W.P.J., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J.M., de Groot, Jan Willem B., Haanen, John B., Kapiteijn, Ellen, Bloem, Manja, Piersma, Djura, van Rijn, Rozemarijn S., Stevense-den Boer, Marion, van der Veldt, Astrid A.M., Vreugdenhil, Gerard, Wouters, Michel W.J.M., Blokx, Willeke A.M., Suijkerbuijk, Karijn P.M., Fehrmann, Rudolf S.N., and Hospers, Geke A.P.

Abstract

The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with ICIs. Data from advanced melanoma patients with BM treated with ICIs in any line between 2013 and 2020 were obtained from the Dutch Melanoma Treatment Registry. Patients were included from the time of the treatment of BM with ICIs. Survival tree analysis was performed with clinicopathological parameters as potential classifiers and overall survival (OS) as the response variable. In total, 1278 patients were included. Most patients were treated with ipilimumab–nivolumab combination therapy (45%). The survival tree analysis resulted in 31 subgroups. The median OS ranged from 2.7 months to 35.7 months. The strongest clinical parameter associated with survival in advanced melanoma patients with BM was the serum lactate dehydrogenase (LDH) level. Patients with elevated LDH levels and symptomatic BM had the worst prognosis. The clinicopathological classifiers identified in this study can contribute to optimizing clinical studies and can aid doctors in giving an indication of the patients’ survival based on their baseline and disease characteristics.

Published
2023

19. Table S1 from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Author

Bouwstra, Renée, primary, He, Yuan, primary, de Boer, Janneke, primary, Kooistra, Hilde, primary, Cendrowicz, Ewa, primary, Fehrmann, Rudolf S.N., primary, Ammatuna, Emanuele, primary, zu Eulenburg, Christine, primary, Nijland, Marcel, primary, Huls, Gerwin, primary, Bremer, Edwin, primary, and van Meerten, Tom, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure Legends from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Author

Bouwstra, Renée, primary, He, Yuan, primary, de Boer, Janneke, primary, Kooistra, Hilde, primary, Cendrowicz, Ewa, primary, Fehrmann, Rudolf S.N., primary, Ammatuna, Emanuele, primary, zu Eulenburg, Christine, primary, Nijland, Marcel, primary, Huls, Gerwin, primary, Bremer, Edwin, primary, and van Meerten, Tom, primary

Published
2023
Full Text
View/download PDF

21. Data from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Author

Bouwstra, Renée, primary, He, Yuan, primary, de Boer, Janneke, primary, Kooistra, Hilde, primary, Cendrowicz, Ewa, primary, Fehrmann, Rudolf S.N., primary, Ammatuna, Emanuele, primary, zu Eulenburg, Christine, primary, Nijland, Marcel, primary, Huls, Gerwin, primary, Bremer, Edwin, primary, and van Meerten, Tom, primary

Published
2023
Full Text
View/download PDF

22. Figure S1, S2, S3, S4 from CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Author

Bouwstra, Renée, primary, He, Yuan, primary, de Boer, Janneke, primary, Kooistra, Hilde, primary, Cendrowicz, Ewa, primary, Fehrmann, Rudolf S.N., primary, Ammatuna, Emanuele, primary, zu Eulenburg, Christine, primary, Nijland, Marcel, primary, Huls, Gerwin, primary, Bremer, Edwin, primary, and van Meerten, Tom, primary

Published
2023
Full Text
View/download PDF

23. Additional file 1 of Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma

Author

Visconti, Alessia, Rossi, Niccolò, Deriš, Helena, Lee, Karla A, Hanić, Maja, Trbojević-Akmačić, Irena, Thomas, Andrew M., Bolte, Laura A., Björk, Johannes R., Hooiveld-Noeken, Jahlisa S., Board, Ruth, Harland, Mark, Newton-Bishop, Julia, Harries, Mark, Sacco, Joseph J., Lorigan, Paul, Shaw, Heather M., de Vries, Elisabeth G.E., Fehrmann, Rudolf S.N., Weersma, Rinse K., Spector, Tim D., Nathan, Paul, Hospers, Geke A. P., Sasieni, Peter, Bataille, Veronique, Lauc, Gordan, and Falchi, Mario

Abstract

Additional file 1: Figure 1. Representative chromatogram of total human plasma/serum N-glycome separated byHILIC-UPLC into 39 N-glycan peaks (GP1-GP39). Figure 2. Swimmer plot for the 88 patients with advanced melanoma included in this study. Figure 3. Pearson's correlation among the measured N-glycan and derived traits associated with overall response rate in 88 patients with advanced melanoma. Figure 4. Significant association between directly measured serum N-glycans and overall response rate. Figure 5. Kaplan-Meier progression-free survival curves in 88 patients with advanced melanoma (directly measured N-glycans). Figure 6. Diagnostic plots for Cox proportional hazards regression model of survival time on sex, age at diagnosis of advanced melanoma, BMI, dichotomized LDH levels, and ECOG performance-status. Figure 7. Kaplan-Meier overall survival curves in 88 patients with advanced melanoma (directly measured N-glycans).

Published
2023
Full Text
View/download PDF

24. Figure S1 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Author

Caumanns, Joseph J., primary, Berns, Katrien, primary, Wisman, G. Bea A., primary, Fehrmann, Rudolf S.N., primary, Tomar, Tushar, primary, Klip, Harry, primary, Meersma, Gert J., primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Duiker, Evelien W., primary, Weening, Desiree, primary, Itamochi, Hiroaki, primary, Kluin, Roelof J.C., primary, Reyners, Anna K.L., primary, Birrer, Michael J., primary, Salvesen, Helga B., primary, Vergote, Ignace, primary, van Nieuwenhuysen, Els, primary, Brenton, James, primary, Braicu, E. Ioana, primary, Kupryjanczyk, Jolanta, primary, Spiewankiewicz, Beata, primary, Mittempergher, Lorenza, primary, Bernards, René, primary, van der Zee, Ate G.J., primary, and de Jong, Steven, primary

Published
2023
Full Text
View/download PDF

25. Table S2 from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Author

Caumanns, Joseph J., primary, Berns, Katrien, primary, Wisman, G. Bea A., primary, Fehrmann, Rudolf S.N., primary, Tomar, Tushar, primary, Klip, Harry, primary, Meersma, Gert J., primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Duiker, Evelien W., primary, Weening, Desiree, primary, Itamochi, Hiroaki, primary, Kluin, Roelof J.C., primary, Reyners, Anna K.L., primary, Birrer, Michael J., primary, Salvesen, Helga B., primary, Vergote, Ignace, primary, van Nieuwenhuysen, Els, primary, Brenton, James, primary, Braicu, E. Ioana, primary, Kupryjanczyk, Jolanta, primary, Spiewankiewicz, Beata, primary, Mittempergher, Lorenza, primary, Bernards, René, primary, van der Zee, Ate G.J., primary, and de Jong, Steven, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data_clean from 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Author

Moek, Kirsten L., primary, Waaijer, Stijn J.H., primary, Kok, Iris C., primary, Suurs, Frans V., primary, Brouwers, Adrienne H., primary, Menke-van der Houven van Oordt, C. Willemien, primary, Wind, Thijs T., primary, Gietema, Jourik A., primary, Schröder, Carolien P., primary, Mahesh, Shekar V.K., primary, Jorritsma-Smit, Annelies, primary, Lub-de Hooge, Marjolijn N., primary, Fehrmann, Rudolf S.N., primary, de Groot, Derk Jan A., primary, and de Vries, Elisabeth G.E., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table S2 from Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer

Author

Noordhuis, Maartje G., primary, Fehrmann, Rudolf S.N., primary, Wisman, G. Bea A., primary, Nijhuis, Esther R., primary, van Zanden, Jelmer J., primary, Moerland, Perry D., primary, Ver Loren van Themaat, Emiel, primary, Volders, Haukeline H., primary, Kok, Mirjam, primary, ten Hoor, Klaske A., primary, Hollema, Harry, primary, de Vries, Elisabeth G.E., primary, de Bock, Geertruida H., primary, van der Zee, Ate G.J., primary, and Schuuring, Ed, primary

Published
2023
Full Text
View/download PDF

28. Supplementary figures and tables legends from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Author

Caumanns, Joseph J., primary, Berns, Katrien, primary, Wisman, G. Bea A., primary, Fehrmann, Rudolf S.N., primary, Tomar, Tushar, primary, Klip, Harry, primary, Meersma, Gert J., primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Duiker, Evelien W., primary, Weening, Desiree, primary, Itamochi, Hiroaki, primary, Kluin, Roelof J.C., primary, Reyners, Anna K.L., primary, Birrer, Michael J., primary, Salvesen, Helga B., primary, Vergote, Ignace, primary, van Nieuwenhuysen, Els, primary, Brenton, James, primary, Braicu, E. Ioana, primary, Kupryjanczyk, Jolanta, primary, Spiewankiewicz, Beata, primary, Mittempergher, Lorenza, primary, Bernards, René, primary, van der Zee, Ate G.J., primary, and de Jong, Steven, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods from Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Author

Caumanns, Joseph J., primary, Berns, Katrien, primary, Wisman, G. Bea A., primary, Fehrmann, Rudolf S.N., primary, Tomar, Tushar, primary, Klip, Harry, primary, Meersma, Gert J., primary, Hijmans, E. Marielle, primary, Gennissen, Annemiek M.C., primary, Duiker, Evelien W., primary, Weening, Desiree, primary, Itamochi, Hiroaki, primary, Kluin, Roelof J.C., primary, Reyners, Anna K.L., primary, Birrer, Michael J., primary, Salvesen, Helga B., primary, Vergote, Ignace, primary, van Nieuwenhuysen, Els, primary, Brenton, James, primary, Braicu, E. Ioana, primary, Kupryjanczyk, Jolanta, primary, Spiewankiewicz, Beata, primary, Mittempergher, Lorenza, primary, Bernards, René, primary, van der Zee, Ate G.J., primary, and de Jong, Steven, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figures S1-S2 from Involvement of the TGF-β and β-Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer

Author

Noordhuis, Maartje G., primary, Fehrmann, Rudolf S.N., primary, Wisman, G. Bea A., primary, Nijhuis, Esther R., primary, van Zanden, Jelmer J., primary, Moerland, Perry D., primary, Ver Loren van Themaat, Emiel, primary, Volders, Haukeline H., primary, Kok, Mirjam, primary, ten Hoor, Klaske A., primary, Hollema, Harry, primary, de Vries, Elisabeth G.E., primary, de Bock, Geertruida H., primary, van der Zee, Ate G.J., primary, and Schuuring, Ed, primary

Published
2023
Full Text
View/download PDF

31. The FIGNL1-interacting protein C1orf112 is synthetic lethal with PICH and mediates RAD51 retention on chromatin

Author

Stok, Colin, primary, van den Tempel, Nathalie, additional, Everts, Marieke, additional, Wierenga, Elles, additional, Bakker, Femke, additional, Kok, Yannick, additional, Alves, Inês Teles, additional, Jae, Lucas T., additional, Bhattacharya, Arkajyoti, additional, Karanika, Elefteria, additional, Perepelkina, Polina, additional, Bergink, Steven, additional, Chan, Kok-Lung, additional, de Boer, H. Rolf, additional, Fehrmann, Rudolf S.N., additional, and van Vugt, Marcel A.T.M., additional

Published
2022
Full Text
View/download PDF

33. Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours

Author

Oosting, Sjoukje F., van der Veldt, Astrid A.M., Fehrmann, Rudolf S.N., GeurtsvanKessel, Corine H., van Binnendijk, Rob S., Dingemans, Anne Marie C., Smit, Egbert F., Hiltermann, T. Jeroen N., den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T., Bhattacharya, Arkajyoti, de Wilt, Faye, Boerma, Annemarie, van Zijl, Lisanne, Rimmelzwaan, Guus F., Kvistborg, Pia, van Els, Cecile A.C.M., Rots, Nynke Y., van Baarle, Debbie, Haanen, John B.A.G., de Vries, Elisabeth G.E., Oosting, Sjoukje F., van der Veldt, Astrid A.M., Fehrmann, Rudolf S.N., GeurtsvanKessel, Corine H., van Binnendijk, Rob S., Dingemans, Anne Marie C., Smit, Egbert F., Hiltermann, T. Jeroen N., den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T., Bhattacharya, Arkajyoti, de Wilt, Faye, Boerma, Annemarie, van Zijl, Lisanne, Rimmelzwaan, Guus F., Kvistborg, Pia, van Els, Cecile A.C.M., Rots, Nynke Y., van Baarle, Debbie, Haanen, John B.A.G., and de Vries, Elisabeth G.E.

Published
2022

34. Intraoperative MET-receptor targeted fluorescent imaging and spectroscopy for lymph node detection in papillary thyroid cancer:novel diagnostic tools for more selective central lymph node compartment dissection

Author

Jonker, Pascal K.C., Metman, Madelon J.H., Sondorp, Luc H.J., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, Links, Thera P., van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Coppes, Robert P., Robinson, Dominic J., van Dam, Gooitzen M., van Hemel, Bettien M., Fehrmann, Rudolf S.N., Kruijff, Schelto, Jonker, Pascal K.C., Metman, Madelon J.H., Sondorp, Luc H.J., Sywak, Mark S., Gill, Anthony J., Jansen, Liesbeth, Links, Thera P., van Diest, Paul J., van Ginhoven, Tessa M., Löwik, Clemens W.G.M., Nguyen, Anh H., Coppes, Robert P., Robinson, Dominic J., van Dam, Gooitzen M., van Hemel, Bettien M., Fehrmann, Rudolf S.N., and Kruijff, Schelto

Abstract

Purpose: Patients undergoing prophylactic central compartment dissection (PCLND) for papillary thyroid cancer (PTC) are often overtreated. This study aimed to determine if molecular fluorescence-guided imaging (MFGI) and spectroscopy can be useful for detecting PTC nodal metastases (NM) and to identify negative central compartments intraoperatively. Methods: We used a data-driven prioritization strategy based on transcriptomic profiles of 97 primary PTCs and 80 normal thyroid tissues (NTT) to identify tumor-specific antigens for a clinically available near-infrared fluorescent tracer. Protein expression of the top prioritized antigen was immunohistochemically validated with a tissue microarray containing primary PTC (n = 741) and NTT (n = 108). Staining intensity was correlated with 10-year locoregional recurrence-free survival (LRFS). A phase 1 study (NCT03470259) with EMI-137, targeting MET, was conducted to evaluate safety, optimal dosage for detecting PTC NM with MFGI, feasibility of NM detection with quantitative fiber-optic spectroscopy, and selective binding of EMI-137 for MET. Results: MET was selected as the most promising antigen. A worse LRFS was observed in patients with positive versus negative MET staining (81.9% versus 93.2%; p = 0.02). In 19 patients, no adverse events related to EMI-137 occurred. 0.13 mg/kg EMI-137 was selected as optimal dosage for differentiating NM from normal lymph nodes using MFGI (p < 0.0001) and spectroscopy (p < 0.0001). MFGI identified 5/19 levels (26.3%) without NM. EMI-137 binds selectively to MET. Conclusion: MET is overexpressed in PTC and associated with increased locoregional recurrence rates. Perioperative administration of EMI-137 is safe and facilitates NM detection using MFGI and spectroscopy, potentially reducing the number of negative PCLNDs with more than 25%. Clinical trial registration.: NCT03470259.

Published
2022

35. Whole-body CD8+ T cell visualization before and during cancer immunotherapy: a phase 1/2 trial

Author

Hart- en Vaatziekten Team A, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S.N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J.A., de Vries, Elisabeth G.E., Hart- en Vaatziekten Team A, Epi Kanker Team C, Cancer, JC onderzoeksprogramma Cancer, Kist de Ruijter, Laura, van de Donk, Pim P., Hooiveld-Noeken, Jahlisa S., Giesen, Danique, Elias, Sjoerd G., Lub-de Hooge, Marjolijn N., Oosting, Sjoukje F., Jalving, Mathilde, Timens, Wim, Brouwers, Adrienne H., Kwee, Thomas C., Gietema, Jourik A., Fehrmann, Rudolf S.N., Fine, Bernard M., Sanabria Bohórquez, Sandra M., Yadav, Mahesh, Koeppen, Hartmut, Jing, Jing, Guelman, Sebastian, Lin, Mark T., Mamounas, Michael J., Eastham, Jeffrey Ryan, Kimes, Patrick K., Williams, Simon P., Ungewickell, Alexander, de Groot, Derk J.A., and de Vries, Elisabeth G.E.

Published
2022

36. MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

Author

Hubrecht Institute with UMC, Zimmerli, Dario, Brambillasca, Chiara S., Talens, Francien, Bhin, Jinhyuk, Linstra, Renske, Romanens, Lou, Bhattacharya, Arkajyoti, Joosten, Stacey E.P., Da Silva, Ana Moises, Padrao, Nuno, Wellenstein, Max D., Kersten, Kelly, de Boo, Mart, Roorda, Maurits, Henneman, Linda, de Bruijn, Roebi, Annunziato, Stefano, van der Burg, Eline, Drenth, Anne Paulien, Lutz, Catrin, Endres, Theresa, van de Ven, Marieke, Eilers, Martin, Wessels, Lodewyk, de Visser, Karin E., Zwart, Wilbert, Fehrmann, Rudolf S.N., van Vugt, Marcel A.T.M., Jonkers, Jos, Hubrecht Institute with UMC, Zimmerli, Dario, Brambillasca, Chiara S., Talens, Francien, Bhin, Jinhyuk, Linstra, Renske, Romanens, Lou, Bhattacharya, Arkajyoti, Joosten, Stacey E.P., Da Silva, Ana Moises, Padrao, Nuno, Wellenstein, Max D., Kersten, Kelly, de Boo, Mart, Roorda, Maurits, Henneman, Linda, de Bruijn, Roebi, Annunziato, Stefano, van der Burg, Eline, Drenth, Anne Paulien, Lutz, Catrin, Endres, Theresa, van de Ven, Marieke, Eilers, Martin, Wessels, Lodewyk, de Visser, Karin E., Zwart, Wilbert, Fehrmann, Rudolf S.N., van Vugt, Marcel A.T.M., and Jonkers, Jos

Published
2022

37. Survival-related profile, pathways, and transcription factors in ovarian cancer

Author

Crijns, Anne P.G., Fehrmann, Rudolf S.N., de Jong, Steven, Gerbens, Frans, Meersma, Gert Jan, Klip, Harry G., Hollema, Harry, Hofstra, Robert M.W., te Meerman, Gerard J., de Vries, Elisabeth G.E., and van der Zee, Ate G.J.

Subjects
Development and progression, Research, Genetic aspects, Patient outcomes, Outcome and process assessment (Medical care) -- Research, Cellular signal transduction -- Research -- Genetic aspects, DNA binding proteins -- Research -- Genetic aspects, Ovarian cancer -- Genetic aspects -- Development and progression -- Patient outcomes -- Research, Outcome and process assessment (Health Care) -- Research
Abstract

Introduction Ovarian carcinoma is the leading cause of death from gynecologic malignancies in the Western world [1]. Debulking surgery followed by platinum-based chemotherapy is considered standard of care for patients [...], Background Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways. The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers. Methods and Findings According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using ~35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset. Conclusions Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.

Published
2009

39. MYC promotes immune-suppression in TNBC via inhibition of IFN signaling

Author

Zimmerli, Dario, primary, Brambillasca, Chiara S, additional, Talens, Francien, additional, Bhin, Jinhyuk, additional, Bhattacharya, Arkajyoti, additional, Joosten, Stacey E.P., additional, Da Silva, Ana Moises, additional, Wellenstein, Max D., additional, Kersten, Kelly, additional, de Boo, Mart, additional, Roorda, Maurits, additional, Henneman, Linda, additional, de Bruijn, Roebi, additional, Annunziato, Stefano, additional, van der Burg, Eline, additional, Drenth, Anne Paulien, additional, Lutz, Catrin, additional, van de Ven, Marieke, additional, Wessels, Lodewyk, additional, de Visser, Karin, additional, Zwart, Wilbert, additional, Fehrmann, Rudolf S.N., additional, van Vugt, Marcel A.T.M., additional, and Jonkers, Jos, additional

Published
2021
Full Text
View/download PDF

41. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9

Author

Janse, Marcel, Lamberts, Laetitia E., Franke, Lude, Raychaudhuri, Soumya, Ellinghaus, Eva, Boberg, Kirsten Muri, Melum, Espen, Folseraas, Trine, Schrumpf, Erik, Bergquist, Annika, Björnsson, Einar, Fu, Jingyuan, Westra, Harm Jan, Groen, Harry J.M., Fehrmann, Rudolf S.N., Smolonska, Joanna, van den Berg, Leonard H., Ophoff, Roel A., Porte, Robert J., Weismüller, Tobias J., Wedemeyer, Jochen, Schramm, Christoph, Sterneck, Martina, Günther, Rainer, Braun, Felix, Vermeire, Severine, Henckaerts, Liesbet, Wijmenga, Cisca, Ponsioen, Cyriel Y., Schreiber, Stefan, Karlsen, Tom H., Franke, Andre, and Weersma, Rinse K.

Published
2011
Full Text
View/download PDF

43. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Author

Bouwstra, Renée, primary, He, Yuan, additional, de Boer, Janneke, additional, Kooistra, Hilde, additional, Cendrowicz, Ewa, additional, Fehrmann, Rudolf S.N., additional, Ammatuna, Emanuele, additional, zu Eulenburg, Christine, additional, Nijland, Marcel, additional, Huls, Gerwin, additional, Bremer, Edwin, additional, and van Meerten, Tom, additional

Published
2019
Full Text
View/download PDF

44. 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Author

Moek, Kirsten L., primary, Waaijer, Stijn J.H., additional, Kok, Iris C., additional, Suurs, Frans V., additional, Brouwers, Adrienne H., additional, Menke-van der Houven van Oordt, C. Willemien, additional, Wind, Thijs T., additional, Gietema, Jourik A., additional, Schröder, Carolien P., additional, Mahesh, Shekar V.K., additional, Jorritsma-Smit, Annelies, additional, Lub-de Hooge, Marjolijn N., additional, Fehrmann, Rudolf S.N., additional, de Groot, Derk Jan A., additional, and de Vries, Elisabeth G.E., additional

Published
2019
Full Text
View/download PDF

45. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma

Author

Caumanns, Joseph J., primary, Berns, Katrien, additional, Wisman, G. Bea A., additional, Fehrmann, Rudolf S.N., additional, Tomar, Tushar, additional, Klip, Harry, additional, Meersma, Gert J., additional, Hijmans, E. Marielle, additional, Gennissen, Annemiek M.C., additional, Duiker, Evelien W., additional, Weening, Desiree, additional, Itamochi, Hiroaki, additional, Kluin, Roelof J.C., additional, Reyners, Anna K.L., additional, Birrer, Michael J., additional, Salvesen, Helga B., additional, Vergote, Ignace, additional, van Nieuwenhuysen, Els, additional, Brenton, James, additional, Braicu, E. Ioana, additional, Kupryjanczyk, Jolanta, additional, Spiewankiewicz, Beata, additional, Mittempergher, Lorenza, additional, Bernards, René, additional, van der Zee, Ate G.J., additional, and de Jong, Steven, additional

Published
2018
Full Text
View/download PDF

47. Theranostics Using Antibodies and Antibody-Related Therapeutics

Author

Moek, Kirsten L., primary, Giesen, Danique, additional, Kok, Iris C., additional, de Groot, Derk Jan A., additional, Jalving, Mathilde, additional, Fehrmann, Rudolf S.N., additional, Lub-de Hooge, Marjolijn N., additional, Brouwers, Adrienne H., additional, and de Vries, Elisabeth G.E., additional

Published
2017
Full Text
View/download PDF

48. Functional Genomic mRNA Profiling of Colorectal Adenomas: Identification and in vivo Validation of CD44 and Splice Variant CD44v6 as Molecular Imaging Targets

Author

Hartmans, Elmire, primary, Orian-Rousseau, Veronique, additional, Matzke-Ogi, Alexandra, additional, Karrenbeld, Arend, additional, de Groot, Derk Jan A., additional, de Jong, Steven, additional, van Dam, Gooitzen M., additional, Fehrmann, Rudolf S.N., additional, and Nagengast, Wouter B., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results